FPH’s stock stages a relief rally after investor fears allayed
The dual-listed medical device company has delivered strong revenue and product growth for 2026 despite US tariffs and the Middle East conflict.
F&P has shifted around production volumes to lessen US tariff impacts.
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Dual-listed medical device company Fisher & Paykel Healthcare has delivered strong revenue and profit growth for 2026 despite headwinds from the Middle East conflict and US tariffs.
There had been a sell-off of the stock prior to the results announcement with fears of a downgrade in its FY27
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Subscribe Now
Monthly Premium Online Subscription
NZ$49.95 / monthly
Subscribe Now
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Subscribe Now
Yearly Premium Online Subscription
NZ$499.00 / yearly
Subscribe Now
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Subscribe Now
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Subscribe Now
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
